Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugspriority health Medicare MPSERS formulary Coverage…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentpriority healthPolicy N/A

    Priority Health Medicare MPSERS Formulary (Drug List)

    Customize your policy alerts

    Sign up for all priority health policy alerts

    Know when priority health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the Priority Health Medicare MPSERS formulary describing covered prescription drugs, coverage rules (prior authorization, step therapy, quantity limits), member protections, and how to request exceptions; it affects Priority Health Medicare MPSERS plan members and their prescribers and pharmacies.

    Policy Summary
    Payerpriority health
    PolicyPriority Health Medicare MPSERS Formulary (Drug List)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewMay 21, 2026
    Next Review DateN/A
    Key ActionObtain required prior authorization (PA) before submitting claims for drugs listed with PA to avoid denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5/21/2026formulary last updated
    6/1/2026current as of
    30 daysmember notice
    72 hrsexception timeline
    QL examplesQL examples

    Coverage rules and formulary application

    Standard formulary coverage

    Covered when ALL of the following are met:

    Standard coverage conditions: Drug is listed on the formulary AND drug is medically necessary AND prescription is filled at a Priority Health Medicare network pharmacy

    See Evidence of Coverage for filling rules

    Formulary change and member protections

    Mid‑year formulary changes and member protections — Covered when the listed member protections or notices are followed:

    Immediate change triggers: Addition of a new generic or certain biosimilar versions or withdrawal from market may lead to immediate formulary removal or tier movement

    If an immediate change affects a member currently taking the drug, member or prescriber may request an exception to continue therapy

    Policy Summary
    Payerpriority health
    PolicyPriority Health Medicare MPSERS Formulary (Drug List)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewMay 21, 2026
    Next Review DateN/A
    Key ActionObtain required prior authorization (PA) before submitting claims for drugs listed with PA to avoid denial.
    SourceLink
    On This Page
    Coverage rules and formulary applicationAbbreviations, tiers, and code legendWhat prescribers and pharmacies must doLegend: tiers, abbreviations, and termsProtections for members already receiving therapyStep therapy flags and examplesNumerical dispensing limits by productHome infusion and billing channel notesBiologic and biosimilar handling
    Other mid-year changes that affect current therapy: When a brand is removed because a generic or biosimilar is added, or when PA/QL/ST is newly applied or a drug is moved to a higher cost‑sharing tier, Priority Health Medicare will notify affected members at least 30 days before the change OR provide a 30‑day supply at refill30 days

    Members may request a formulary exception to continue their current drug under the protection rules

    Withdrawn-from-market protections: If a drug is withdrawn from market by the manufacturer or removed for safety/effectiveness reasons, Priority Health Medicare may immediately remove it and will later notify members who take the drug

    Members and prescribers should refer to mailed notice and Exception process

    Formulary exceptions

    Formulary exceptions — Decision timelines and required documentation:

    Exception approval standard: Prescriber must provide medical rationale that formulary alternatives, lower cost‑sharing drugs, or application of the restriction would not be as effective or would cause adverse effects72 hours (24 expedited)

    Standard decision within 72 hours; expedited (24‑hour) review available when waiting could cause serious harm

    Types of exceptions available: Request to cover a non‑formulary drug; request to waive PA, ST, or QL; request to tier‑down a covered drug (except specialty tier) — prescriber must explain medical reasons

    If approved to cover a non‑formulary drug it will be covered at a predetermined cost‑sharing level

    Temporary/transition coverage

    Temporary and transition coverage rules — Covered when the transition conditions are met:

    New or continuing member transition supply: Plan may cover a temporary 30‑day supply for drugs not on formulary or with restriction during the first 90 days of membership30 days

    If prescription is written for fewer days, refills may be allowed to reach a 30‑day supply; coverage ends if exception/authorization not approved

    Long‑term care residents: If long‑term care resident past first 90 days needs a non‑formulary or restricted drug, plan will cover a 31‑day emergency supply while exception is pursued31 days

    Applies when access is limited or member in institutional setting

    Level‑of‑care changes: Members experiencing a change in level of care are provided a transition supply of at least 30 days unless prescription written for fewer days30 days

    Supports continuity while a formulary decision or exception is pursued

    Drug-specific coverage with PA/QL constraints

    Drug‑specific coverage with PA/QL constraints — Covered when the product line entry and its Requirements/Limits are satisfied:

    Formulary entry compliance: Each drug entry shows a Tier and may list Requirements/Limits (for example: PA, QL, ST, HI, LA, B/D). Coverage is subject to meeting the listed Requirements/Limits for that product line

    Examples in the formulary: VERSACLOZ (PA; QL 540 ML/30 days); OZEMPIC (PA; QL 3 ML/28 days); MOUNJARO (PA; QL 2 ML/28 days)

    Prior Authorization examples: When 'PA' is listed for a drug line the prescriber must obtain prior authorization before coverage; failure to obtain PA may result in denial

    Examples: clozapine dispersible (PA); VERSACLOZ (PA; QL 540 ML/30 days)

    Quantity limit examples: When 'QL' is listed the product is limited to the stated quantity per time period and claims exceeding QL may be denied without an approved exceptionExamples per product (EA or ML) shown on formulary

    Examples: JANUMET XR QL 60 EA/30 days; OZEMPIC QL 3 ML/28 days; XIFAXAN QL varies by strength

    General coverage rules

    General coverage rules — Coverage depends on tier and any listed requirements:

    Tier determines coverage level: Drugs listed with a Tier (T1–T6) indicate coverage/cost‑sharing level; Tier 5 denotes specialty drugs (30‑day supply only)

    See formulary legend for tier definitions and supply restrictions

    Additional requirement flags: Drugs may also carry flags such as PA (Prior Authorization), QL (Quantity Limit), ST (Step Therapy) and B/D (Part B vs Part D) which must be met for coverage

    Examples: REDEMPLO (PA; QL 0.5 mL/84 days); VERQUVO (PA; QL 30 EA/30 days); REPATHA products (PA; specific QLs)

    Product-level coverage controls

    Product‑level coverage controls — Covered when meeting the product line's specified payer requirements:

    Formulary entry controls: Each listed drug line includes tier assignment and may include one or more of: QL (quantity limit), PA (prior authorization), B/D (Part B vs Part D), LA (limited availability), NE (No Express Scripts), ED (Excluded Drug) — coverage follows these flags

    Providers must follow PA and QL rules where present and submit required documentation

    Excluded drug behavior: Drugs marked 'ED' are not normally covered under the Medicare Prescription Drug Plan and will be denied if billed

    Examples of ED products are listed in the formulary; payments for ED drugs do not count toward catastrophic coverage

    Home infusion / benefit channel: When a product is annotated 'HI' it may be covered under the medical/home infusion benefit and billing or site‑of‑care rules (B/D) must be followed

    Contact CustomerCare for Home Infusion or Part B/Part D billing guidance

    In the formulary legend ED stands for Excluded Drug. An ED-marked prescription drug is not normally covered under a Medicare Prescription Drug Plan; amounts paid for an ED drug do not count toward a member's total drug costs and do not help the member qualify for catastrophic coverage. Members who receive extra help will not receive assistance for drugs designated ED.

    The formulary uses ED in the abbreviations section to identify excluded products. Entries elsewhere (for example specialty antidepressants and other therapeutic sections) reference requirements such as PA, QL, and occasionally NE (No Express Scripts), but when an item is labeled ED it indicates exclusion from coverage under the plan.

    The formulary also uses the NE and ED annotations in the Requirements/Limits column. NE denotes No Express Scripts (restricted fill channel), while ED denotes an Excluded Drug. When either code appears on a drug line it signals restricted access or that the product is not covered per the formulary legend.

    Within the provided excerpt there are no explicit clinical exclusion criteria (for example, no medically necessary clinical test or diagnosis listed that would bar coverage). The document instead flags products with shorthand codes (e.g., ED) and directs readers to the formulary legend for meaning.

    Although the abbreviation ED is defined in the legend, these chunks do not list a comprehensive set of excluded drugs; the legend refers to ED but the specific excluded items are not exhaustively enumerated in this excerpt.

    This section reiterates the ED abbreviation in the legend, but no individual excluded-drug lines are provided here. The document shows how ED would be applied, yet specific excluded drug entries are not present in these chunks.

    Some formulary entries are explicitly marked ED in the drug lists. Examples in the dermatology and topical sections include items such as tretinoin (emollient) and various urea external formulations that are flagged ED in the listing.

    Multiple individual products in the excerpt are labeled ED. Notable examples include tretinoin (emollient), several urea external creams/gels, and other items referenced as ED in the dermatologic and topical agent listings.

    Fertility and infertility-related products are assigned a dedicated tier and some are excluded. The formulary shows ED designations for certain agents used in fertility treatment (examples include chorionic gonadotropin intramuscular, hCG injection solution reconstituted 12000 unit, and listed products such as NOVAREL, OVIDREL, and PREGNYL marked ED).

    The formulary notes that Tier 5 (Specialty) drugs are limited to a 30-day supply only. This supply restriction is shown in the tier legend and reiterated across specialty listings.

    Specific products are shown in the respiratory and related sections as ED and therefore will not be covered. Examples called out in the excerpt include benzonatate and certain inhalation sodium chloride/nebulization solutions marked ED.

    In the chunks reviewed there are no explicit statements using the phrase 'not medically necessary.' The formulary uses coverage flags and requirements (e.g., PA, QL, ED) rather than explicit 'not medically necessary' language in these excerpts.

    Abbreviations, tiers, and code legend

    Abbreviations used in formularymixed
    B/DPart B vs. Part D classification; may require additional information to determine coverage setting
    Other abbreviationsmixed
    EAEach
    EDExcluded Drug — not normally covered in Medicare Part D
    Quantity limit notationsmixed
    QL (750 ML per 30 days)Quantity limit for diclofenac sodium external solution 1.5%
    QL (30 EA per 30 days)Quantity limit for mefenamic acid oral
    QL (4 EA per 28 days)Quantity limit for buprenorphine transdermal
    QL (10 EA per 30 days)Quantity limit for fentanyl transdermal patch (selected strengths)
    QL (60 EA per 30 days)Quantity limit for hydromorphone ER tablets (example)
    QL (235.2 ML per 28 days)Quantity limit for ARIKAYCE
    QL (720 ML per 30 days)Quantity limit for tobramycin injection solutions
    Formulary tiersmixed
    T1-T6Formulary drug tier definitions: T1-Preferred generic; T2-Generic; T3-Preferred brand; T4-Non-preferred drug; T5-Specialty; T6-Infertility
    Selected listed products with PA/QLmixedCovered
    XIFAXAN ORAL TABLET 200 MGDrug listed with Tier 4; Requirements: PA; QL (9 EA per 30 days)
    XIFAXAN ORAL TABLET 550 MGDrug listed with Tier 5; Requirements: PA; QL (60 EA per 30 days)
    DIFICID productsmixedCovered
    DIFICID ORAL SUSPENSION RECONSTITUTEDTier 5; Requirements: ST; QL (136 ML per 10 days)
    DIFICID ORAL TABLETTier 5; Requirements: ST; QL (20 EA per 10 days)
    Drugs requiring Home InfusionmixedCovered
    VANCOMYCIN HCL INTRAVENOUS SOLUTIONMultiple IV strengths listed; Requirements: HI
    CEFTRIAXONE SODIUM INJECTION SOLUTIONMultiple strengths listed; Requirements: HI
    PIPERACILLIN-TAZOBACTAM INTRAVENOUS SOLUTIONMultiple strengths listed; Requirements: HI
    Selected anticonvulsant specialty productsmixedCovered
    BRIVARACETAM ORAL SOLUTION/TABLETTier 5; Requirements: PA; QL (600 ML per 30 days for solution; 60 EA per 30 days for tablets)
    EPIDIOLEXTier 5; Requirements: PA; QL (500 ML per 30 days)
    PERAMPANEL ORAL TABLET/SUSPENSIONTier 5; Requirements: PA; QL (30 EA per 30 days for many tablet strengths; 680 ML per 28 days for suspension)
    XCOPRI formulationsTier 5; Requirements: PA; QL (various per-strength limits listed)
    Selected drug-strength entriesmixed
    100 mglomustine oral capsule 100 mg (listed with Tier 5)
    250 mgabiraterone acetate oral tablet 250 mg (QL 120 EA per 30 days)
    Erlotinib strengthsmixed
    100 mgerlotinib HCl oral tablet 100 mg (PA; QL 30 EA per 30 days)
    25 mgerlotinib HCl oral tablet 25 mg (PA; QL 90 EA per 30 days)
    NDC/CPT not presentmixed
    No codes listed
    Quantity limit examplesmixed
    60 EA per 30 daysQuantity limit example for TRADJENTA (from chunk 126)
    2 ML per 28 daysQuantity limit for TRULICITY (from chunk 127)
    620 ML per 30 daysQuantity limit for XARELTO oral suspension (from chunk 137)
    60 ML per 30 daysQuantity limit for enoxaparin prefilled syringes (100 mg/ml,150 mg/ml) (from chunk 135)
    Formulary drug entries with PA/QL notedmixed
    ENTRESTO ORAL CAPSULE SPRINKLEFormulary entry; Tier 3; QL (240 EA per 30 days)
    REDEMPLOTier 5; Requirements/Limits = PA; QL (0.5 ML per 84 days)
    TRYNGOLZATier 5; Requirements/Limits = PA; QL (0.8 ML per 30 days)
    VERQUVOTier 4; Requirements/Limits = PA; QL (30 EA per 30 days)
    REPATHATier 3; Requirements/Limits = PA; QL (2 ML per 28 days)
    REPATHA PUSHTRONEX SYSTEMTier 3; Requirements/Limits = PA; QL (3.5 ML per 30 days)
    REPATHA SURECLICKTier 3; Requirements/Limits = PA; QL (2 ML per 28 days)
    NEXLETOLTier 4; Requirements/Limits = PA; QL (30 EA per 30 days)
    NEXLIZETTier 4; Requirements/Limits = PA; QL (30 EA per 30 days)
    KERENDIATier 4; Requirements/Limits = PA; QL (30 EA per 30 days)
    1–10 of 11
    1/2
    Formulary drug entries (sample from these chunks)mixed
    OTEZLA ORAL TABLET 30 MGDrug listed with Tier 5; Requirements: PA; QL (60 EA per 30 days)
    clotrimazole-betamethasone external creamTier 2; Requirements/Limits = ST
    clotrimazole-betamethasone external lotionTier 4; Requirements/Limits = QL (120 ML per 30 days)
    fluorouracil external cream 5%Tier 2; Requirements/Limits = QL (40 GM per 30 days)
    imiquimod external cream 5%Tier 4; Requirements/Limits = (none listed)
    PANRETINTier 5; Requirements/Limits = PA; QL (60 GM per 30 days)
    SANTYLTier 4; Requirements/Limits = QL (60 GM per 30 days)
    carglumic acid oral tablet solubleTier 5; Requirements/Limits = PA; LA
    KLOR-CON productsTier 2; Requirements/Limits = (none listed)
    magnesium sulfate injection solution 50%Tier 4; Requirements/Limits = (none listed)
    1–10 of 20
    1/2
    Formulary tier legendmixed
    No codes listed
    Referenced NDA identifiersmixed
    nda020503albuterol sulfate HFA inhalation aerosol solution (specific NDA)
    nda020983albuterol sulfate HFA inhalation aerosol solution (specific NDA)
    Example Quantity Limits
    QL (30 EA per 30 days)Example quantity limit used for multiple oral products (e.g., mefenamic acid: QL (30 EA per 30 days)).
    QL (60 EA per 30 days)Common QL applied to extended‑release opioids and other agents (e.g., hydromorphone ER QL (60 EA per 30 days)).
    QL (235.2 ML per 28 days)Example volumetric QL shown for certain inhaled/instilled products (document lists ML‑based limits such as 235.2 ML/28 days).
    QL (750 ML per 30 days)Exact QL for diclofenac sodium external solution 1.5% is listed as QL (750 ML per 30 days).
    QL (10 EA per 30 days)Example QL for selected transdermal fentanyl patches (e.g., fentanyl transdermal patch Requirements/Limits = QL (10 EA per 30 days)).
    Quantity limit examples for specific drugs
    XIFAXAN 200 mgPA; QL (9 EA per 30 days).
    XIFAXAN 550 mgPA; QL (60 EA per 30 days).
    DIFICID oral tabletST; QL (20 EA per 10 days).
    DIFICID oral suspensionST; QL (136 ML per 10 days).
    BRIVARACETAM oral solutionPA; QL (600 ML per 30 days) — example in anticonvulsant group.
    Quantity limits examples — multiple numeric examples
    QL (30 EA per 30 days)Listed for multiple products (e.g., eslicarbazepine acetate 200/400 mg = QL 30 EA per 30 days).
    QL (60 EA per 30 days)Listed for higher‑strength formulations (e.g., eslicarbazepine acetate 600/800 mg = QL 60 EA per 30 days).
    QL (1200 ML per 30 days)Example ML‑based QL (e.g., lacosamide oral solution QL (1200 ML per 30 days)).
    QL (300 ML per 30 days)Example volumetric QL for oral solutions (e.g., memantine oral solution QL (300 ML per 30 days)).
    Common QL examples
    QL (120 EA per 30 days)Listed for some oncology/support products (e.g., ABIRTEGA QL (120 EA per 30 days)).
    QL (30 EA per 30 days)Frequent QL for specialty oral oncology agents (example shown across sections).
    QL (21 EA per 28 days)Example QL interval showing non‑monthly period (e.g., 21 EA per 28 days).
    QL (49 EA per 28 days)Strength‑specific QL shown for agents such as KISQALI FEMARA (49 EA per 28 days for 200 mg dose).
    Quantity limits examples (oncology and targeted therapies)
    PIQRAY 250 mgPA; QL (56 EA per 28 days).
    QINLOCKPA; QL (90 EA per 30 days).
    REVUFORJ 110 mgPA; QL (120 EA per 30 days).
    VITRAKVI oral solutionPA; QL (300 ML per 30 days).
    Sample QL thresholds and mixed-format examples
    Sample mixed QLsExamples in formulary include QL (30 EA per 30 days), QL (3 ML per 28 days), QL (540 ML per 30 days).
    OZEMPIC formulationsPA; QL (3 ML per 28 days) for listed OZEMPIC pen presentations.
    PAXLOVIDQL (40 EA per 180 days) for certain PAXLOVID listings (example of longer period QL).
    TRULICITY auto-injectorQL (2 ML per 28 days) shown for injectable pen products.
    Examples of quantity limits — ML and EA style entries
    Enoxaparin prefilled syringesQL examples shown as ML per 30 days (e.g., 18 ML/24 ML/36 ML per 30 days depending on strength).
    XARELTO oral suspension (reconstituted)QL (620 ML per 30 days).
    SOLIQUAQL (15 ML per 25 days) — example of nonstandard period.
    XARELTO oral tablet 10 mgQL (30 EA per 30 days).
    Quantity limits examples (cardiovascular and injectables)
    ENTRESTO ORAL CAPSULE SPRINKLEQL (240 EA per 30 days) shown for specific formulations.
    REPATHA productsPA; QL (REPATHA 2 ML per 28 days; REPATHA PUSHTRONEX 3.5 ML per 30 days).
    NEXLETOL / NEXLIZETPA; QL (30 EA per 30 days).
    REDEMPLO / TRYNGOLZA / VERQUVO examplesMultiple PA and QL examples are listed for specialty cardiovascular agents (various EA/ML limits).
    Quantity limits examples (mixed units and biologics)
    Various EA/ML/GM limitsDocument shows QLs across units (EA, ML, GM) such as 30 EA/30 days; 2 ML/28 days; 3.5 ML/30 days; 120 EA/30 days depending on product.
    REPATHA SURECLICKPA; QL (2 ML per 28 days).
    TRADJENTAQL (30 EA per 30 days) (alternate listing QL 60 EA per 30 days also present).
    REPATHA (pushtronex/system) examplesREPATHA PUSHTRONEX SYSTEM QL (3.5 ML per 30 days) — actionable ML‑based QL for injectables.
    Examples including imiquimod, carglumic acid, KLOR-CON, magnesium sulfate
    Imiquimod external cream 5%Listed (imiquimod external cream 5%), Requirements/Limits = (none listed) — product present in formulary entries.
    Carglumic acid oral tablet solubleTier 5; Requirements/Limits = PA; LA (limited availability).
    KLOR-CON productsKLOR-CON listed (tier 2) with no Requirements/Limits specified in excerpt.
    Magnesium sulfate injection solution 50%Listed among electrolyte/mineral products (tiering present; no QL shown in excerpt).
    Formulary entries: tolvaptan, RELISTOR, GATTEX, REZDIFFRA, VOWST, PROLASTIN-C
    tolvaptan (oral tablet)Tier 5; Requirements/Limits = PA; QL (120 EA per 30 days).
    RELISTOR ORALTier 5; Requirements/Limits = PA; QL (90 EA per 30 days).
    RELISTOR SUBCUTANEOUSTier 5; Requirements/Limits = PA (subcutaneous form).
    GATTEXTier 5; Requirements/Limits = PA (listed among specialty GI agents).
    REZDIFFRATier 5; Requirements/Limits = PA; QL (30 EA per 30 days).
    VOWSTTier 5; Requirements/Limits = PA; QL (12 EA per 3 days).
    PROLASTIN-C INTRAVENOUS SOLUTIONTier 5; Requirements/Limits = PA; LA (limited availability) — listed in blood products/enzymes.

    What prescribers and pharmacies must do

    Prior Authorization

    Prior authorization required — check formulary Requirements/Limits

    Check the Requirements/Limits column in the formulary (beginning on page 12) for any drug listed with 'PA' — prior authorization must be obtained from Priority Health Medicare before filling those prescriptions; failure to obtain PA may result in the plan not covering the drug.

    • Look up the drug on the formulary and confirm 'PA' in the Requirements/Limits column before dispensing.
    • If PA is required, submit the prescriber’s request and supporting documentation per the plan process prior to fill.
    Prior Authorization

    PA required for specified medications (e.g., lidocaine patch, ARIKAYCE, colistimethate, daptomycin)

    Obtain prior authorization for specific listed products that show 'PA' (examples in the formulary include lidocaine patch products, ARIKAYCE, colistimethate, and daptomycin) before dispensing or billing.

    • Lidocaine 5% external patch entries are marked PA; verify and secure authorization before fill.
    • ARIKAYCE is listed with PA; follow PA process and note any QL/HI annotations.
    Prior Authorization

    XIFAXAN requires PA and strength-specific quantity limits

    XIFAXAN (rifaximin) oral tablets require prior authorization and are subject to quantity limits — confirm strength-specific QL when submitting a PA.

    • XIFAXAN 200 mg: PA; QL 9 EA per 30 days.
    • XIFAXAN 550 mg: PA; QL 60 EA per 30 days.
    Prior Authorization

    DIFICID: prior authorization, step therapy, and quantity limits

    DIFICID (fidaxomicin) oral tablet and suspension require step therapy and prior authorization and are quantity‑limited; submit documentation showing ST criteria met and request PA referencing the listed QL.

    • DIFICID oral tablet: ST; QL 20 EA per 10 days.
    • DIFICID oral suspension (reconstituted): ST; QL 136 ML per 10 days.
    Prior Authorization

    Anticonvulsant products require PA and have quantity limits

    Selected anticonvulsant and specialty neurology products are listed with PA and QL; providers must request prior authorization and include any required clinical documentation to support the requested quantity.

    • Brivaracetam oral solution: PA; QL 600 ML per 30 days.
    • Brivaracetam tablets: PA; QL 60 EA per 30 days.
    • EPIDIOLEX: PA; QL 500 ML per 30 days; FINTEPLA and perampanel formulations also show PA and QL as specified.
    Prior Authorization

    PA required for specified anticonvulsant drugs (e.g., eslicarbazepine acetate, rufinamide)

    Obtain prior authorization for the listed anticonvulsant agents (examples include eslicarbazepine acetate and rufinamide) when the formulary entry shows 'PA'; include quantity-limit justification if requesting amounts above the QL.

    • Eslicarbazepine acetate 200/400 mg: PA; QL 30 EA per 30 days.
    • Eslicarbazepine acetate 600/800 mg: PA; QL 60 EA per 30 days.
    • Rufinamide oral suspension/tablet entries are marked PA.
    Prior Authorization

    Prior authorization and quantity/availability limits for many specialty oncology drugs

    Many specialty oncology oral agents require prior authorization and have product‑specific quantity limits or limited‑availability flags; include diagnosis and planned dosing when requesting PA.

    • Examples: ABIRTEGA (abiraterone) QL 120 EA per 30 days; KISQALI entries show PA and QL as listed.
    • Follow the Requirements/Limits column for PA, QL, and LA annotations on each oncology agent.
    Prior Authorization

    PA required for many specialty drugs — confirm PA and QL

    Numerous specialty drugs are designated 'PA' in the formulary; providers must obtain prior authorization before coverage — many of these specialty items also have quantity limits that must be observed.

    • Example specialty entries show PA plus specific QLs (e.g., PIQRAY PA; QL 56 EA per 28 days).
    • Confirm both PA and QL per the drug line before dispensing.
    Prior Authorization

    PA required for listed high‑cost/specialty agents (examples: VERSACLOZ, LIVTENCITY, PREVYMIS, MOUNJARO, OZEMPIC)

    Certain high‑cost or specialty agents (examples include VERSACLOZ, LIVTENCITY, PREVYMIS, MOUNJARO, OZEMPIC) require prior authorization; include clinical rationale and requested quantity per the product QL when submitting PA requests.

    • VERSACLOZ: PA; QL 540 ML per 30 days.
    • MOUNJARO and OZEMPIC entries: PA with specified QLs (e.g., OZEMPIC QL 3 ML per 28 days).
    Prior Authorization

    PA required for certain devices/supplies (e.g., TRULICITY auto‑injector, pen needles)

    Prior authorization is required for certain device and supply items noted as 'PA' in the formulary (examples include TRULICITY auto‑injector and specified pen needles); obtain PA before dispensing supplies or devices.

    • TRULICITY auto‑injector: PA; QL 2 ML per 28 days.
    • Various pen needles and insulin syringe supplies are listed with PA in Requirements/Limits.
    Prior Authorization

    PA required for specialty/high‑cost medications — submit clinical info and dosing

    Specialty/high‑cost medications listed with 'PA' require prior authorization before coverage; review each Requirements/Limits entry and submit PA with the member’s clinical information and dosing to avoid claim denials.

    • Examples: REDEMPLO, TRYNGOLZA, VERQUVO, REPATHA products, NEXLETOL/NEXLIZET are all listed with PA and sometimes QL.
    • Submit supporting clinical documentation and follow the formulary QL when requesting authorization.
    Prior Authorization

    PA required for listed PA drugs (e.g., NEXLETOL, NEXLIZET, REPATHA variants)

    Prior authorization is required for the listed agents (examples include NEXLETOL, NEXLIZET, REPATHA and its presentations); confirm PA and the product‑specific quantity limits before dispensing.

    • REPATHA: PA; QL 2 ML per 28 days (PushtROnex and SureClick variations have their own QLs).
    • NEXLETOL/NEXLIZET: PA; QL 30 EA per 30 days.
    Prior Authorization

    Prior authorization required for listed drugs (e.g., OTEZLA, PANRETIN, RELISTOR, FASENRA, GATTEX)

    Specific drugs in the formulary (e.g., OTEZLA 30 mg, PANRETIN, RELISTOR, FASENRA, GATTEX) are designated 'PA' — obtain prior authorization and document indication and dosing to meet coverage requirements.

    • OTEZLA 30 mg: PA; QL 60 EA per 30 days.
    • PANRETIN: PA; QL 60 GM per 30 days.
    • RELISTOR oral: PA; QL 90 EA per 30 days; RELISTOR subcutaneous: PA.
    Prior Authorization

    PA required for listed specialty/non‑preferred drugs (examples: AMVUTTRA, ENDARI, NULIBRY, PROLASTIN‑C, VYNDAMAX)

    Many specialty or non‑preferred drugs (e.g., AMVUTTRA, ENDARI, NULIBRY, PROLASTIN‑C, VYNDAMAX, testosterone/growth hormone products) are marked 'PA' — request PA and include the clinical justification and, if applicable, limited‑availability documentation.

    • AMVUTTRA: PA; QL 0.5 ML per 90 days.
    • ENDARI: PA; QL 180 EA per 30 days.
    • PROLASTIN‑C intravenous solution: PA; LA (limited availability).
    Prior Authorization

    Prior Authorization required for numerous specialty agents (e.g., LUPRON DEPOT, COSENTYX, DUPIXENT)

    Numerous specialty and biologic agents (examples include LUPRON DEPOT, SIGNIFOR, SOMAVERT, COSENTYX, DUPIXENT) are listed with PA; obtain prior authorization and include dosing/indication to support coverage.

    • LUPRON DEPOT 1‑month and 3‑month kits: PA required.
    • DUPIXENT presentations: PA; QLs vary by presentation (e.g., 3.42 ML per 30 days for 200 mg auto‑injector).
    Prior Authorization

    PA required for selected specialty/high‑cost agents (e.g., BILPREVDA, EVENITY, OXERVATE, XDEMVY)

    Selected specialty/high‑cost agents (e.g., BILPREVDA, EVENITY, OXERVATE, XDEMVY) require prior authorization; follow the Requirements/Limits entry and supply PA with clinical rationale and requested quantity.

    • EVENITY: PA; QL 2.34 ML per 30 days.
    • OXERVATE: PA; QL 28 ML per 30 days.
    • BILPREVDA: PA.
    Prior Authorization

    PA required for many respiratory/pulmonary specialty drugs — confirm PA, QL, and B/D

    Respiratory and pulmonary specialty drugs are often designated 'PA' and may have QL or LA flags — obtain prior authorization and confirm Part B/Part D (B/D) billing designation where shown.

    • CAYSTON, KALYDECO, ORKAMBI, TRIKAFTA entries show PA and various QLs; some CF agents are B/D or LA.
    • Pulmonary antihypertensives (ADEMPAS, ambrisentan, bosentan, OPSUMIT) list PA; QL and LA vary by product.
    Step Therapy

    Step therapy requirement — trial of preferred agents required when 'ST' applies

    Where the formulary flags 'ST' (Step Therapy) on a drug entry, a trial of preferred agent(s) is required before coverage of the listed drug; consult the formulary entry and submit evidence of step completion or justification when requesting PA or an exception.

    • Step therapy may require trying Drug A (preferred) before Drug B (non‑preferred) will be covered.
    • Providers should document prior trials and clinical response when submitting PA or exception requests.
    Step Therapy

    Step Therapy flag — follow ST when indicated on drug entry

    Step Therapy (ST) is used as a requirement on specific drug lines; if 'ST' is indicated for a product, the prescriber must show trial and failure of preferred agent(s) or request an exception.

    • ST is an abbreviation in the formulary legend; follow the product line for whether ST applies.
    • If ST is present, include documentation of prior trials when seeking approval.
    Step Therapy

    DIFICID requires step therapy plus prior authorization and QL adherence

    DIFICID products are subject to step therapy in addition to quantity limits; include documentation that step‑therapy criteria are met when submitting an authorization request for fidaxomicin products.

    • DIFICID oral tablet and suspension: ST; QLs listed (20 EA/10 days for tablets; 136 ML/10 days for suspension).
    Step Therapy

    Step therapy applies to select agents (e.g., FETZIMA, TRINTELLIX, vilazodone)

    Some antidepressants and other agents are marked 'ST' in the formulary (examples include FETZIMA, TRINTELLIX, and vilazodone); if ST applies, document trials of preferred agents before requesting coverage for the ST‑flagged product.

    • FETZIMA: ST; QL 30 EA per 30 days.
    • Vilazodone entries list ST and QL as applicable.
    Note

    Step Therapy noted in legend — follow product‑level ST flags

    The formulary legend defines 'ST' (Step Therapy) as a possible requirement; where an individual drug line is flagged 'ST', follow that requirement and supply documentation of prior trials when seeking approval or exceptions.

    • ST is an abbreviation in the legend—specific ST sequences are not detailed in the drug list; use clinical documentation to support exception or PA requests.
    Denial Risk

    Prior Authorization Denial Risk — failure to obtain PA may lead to denial

    Not obtaining required prior authorization may result in the drug not being covered by Priority Health Medicare; providers should check the formulary and obtain PA before dispensing specialty or PA‑flagged drugs.

    • Claims submitted without required PA may be denied.
    • For specialty/Tier 5 drugs, verify PA and QL before billing to avoid coverage denial.
    Prior Authorization

    XIFAXAN PA/QL — PA required and quantity limits enforced

    Requests for XIFAXAN require prior authorization and are subject to strength‑specific quantity limits; ensure PA submission includes intended dose and requested quantity per the QL.

    • XIFAXAN 200 mg: PA; QL 9 EA per 30 days.
    • XIFAXAN 550 mg: PA; QL 60 EA per 30 days.
    Prior Authorization

    DIFICID ST/QL — step therapy plus quantity limits and PA required

    DIFICID products are subject to step therapy and quantity limits; if prescribing fidaxomicin, include documentation of ST criteria and request PA with the QL‑specified quantity.

    • DIFICID tablet: ST; QL 20 EA per 10 days.
    • DIFICID suspension: ST; QL 136 ML per 10 days.
    Prior Authorization

    Anticonvulsant PA/QL — obtain PA and adhere to QLs for specialty neurology drugs

    Multiple anticonvulsant specialty products (e.g., brivaracetam, EPIDIOLEX, FINTEPLA, perampanel formulations) require prior authorization and have quantity limits; submit PA with dosing and quantity details consistent with the formulary.

    • Brivaracetam solution: PA; QL 600 ML per 30 days.
    • EPIDIOLEX: PA; QL 500 ML per 30 days.
    • Perampanel suspension/tablets: PA; QL as listed (e.g., 680 ML per 28 days for suspension; 30 EA per 30 days for many tablets).
    Documentation Required

    PA/QL triggers — PA or QL flags require authorization or adherence to limits

    Presence of 'PA' or 'QL' in the Requirements/Limits column is a trigger for prior authorization or quantity‑limit review; submit supporting clinical documentation and ensure dispensed quantities do not exceed listed QLs to avoid denials.

    • Examples: eslicarbazepine acetate entries show PA with QLs of 30 or 60 EA per 30 days depending on strength.
    • Providers should document indication and planned dosing in PA submissions.
    Prior Authorization

    Prior Authorization required for many Tier 5/specialty drugs — verify before dispensing

    Prior authorization is required for many Tier 5 (specialty) drugs listed; absence of a PA may lead to claim denial — verify PA requirements before prescribing or dispensing specialty agents.

    • Tier 5 drugs are specialty and limited to 30‑day supply; many have PA flags.
    • Confirm PA and QL for specialty entries (e.g., oncology, biologics) to prevent coverage issues.
    Denial Risk

    Prior authorization requirement — claims may be denied without PA

    Claims for drugs marked 'PA' may be denied if prior authorization is not obtained; follow the formulary Requirements/Limits and obtain PA to prevent coverage denial.

    • When 'PA' appears on the drug line, do not dispense assuming coverage without approval.
    • Submit PA requests with clinical rationale and necessary supporting documents.
    Denial Risk

    PA and QL noncompliance may lead to denial or restricted coverage

    Coverage may be denied or restricted if prior authorization or specified quantity limits are not met for listed drugs (the formulary provides examples such as VERSACLOZ with QL and PA); ensure both PA approval and QL compliance.

    • VERSACLOZ: PA; QL 540 ML per 30 days — lack of PA or exceeding QL may prompt denial.
    • Follow both PA and QL requirements in the drug entry when submitting claims.
    Prior Authorization

    PA required (general) — obtain prior authorization to avoid denial

    Items shown with 'PA' in the formulary will require prior authorization; failure to obtain PA may lead to denial of coverage by Priority Health Medicare.

    • Check the Requirements/Limits column for 'PA' and submit prescriber documentation to obtain authorization before fill.
    Prior Authorization

    Prior authorization triggers for selected agents — submit PA with clinical dosing

    Drugs listed with 'PA' (for example REDEMPLO, TRYNGOLZA, VERQUVO, REPATHA products) may require prior authorization before coverage; submit a PA request with clinical information and planned dosing to meet requirements.

    • REDEMPLO: PA; QL 0.5 ML per 84 days.
    • TRYNGOLZA: PA; QL 0.8 ML per 30 days.
    • VERQUVO: PA; QL 30 EA per 30 days.
    Denial Risk

    Prior authorization risk for specialty drugs — verify PA for Tier 5 agents

    Coverage for many specialty Tier 5 agents may be denied or require prior authorization — verify the PA flag on each specialty product and obtain authorization before dispensing.

    • Specialty agents across sections are frequently flagged PA; ensure PA is in place for coverage.
    • Contact CustomerCare or follow PA submission instructions in the plan materials.
    Denial Risk

    Triggers for prior authorization or denial — follow PA/QL/ED/HI/LA/ST flags

    Entries listing PA, QL, ED, HI, LA or ST are triggers for prior authorization or potential denial — when any of these flags appear, follow the Requirements/Limits instructions and submit required documentation to avoid coverage denial.

    • ED (Excluded Drug) entries will be denied if billed.
    • HI indicates home infusion requirement and may affect benefit/coverage channel.
    Denial Risk

    Denial triggers in list — PA, ED, NE flags require action

    When a listed drug has a PA requirement or is marked ED/NE, coverage may be denied or require further review — obtain PA or confirm exclusion status prior to ordering or billing.

    • Drugs like CAYSTON, KALYDECO, ORKAMBI, TRIKAFTA have 'PA' in Requirements/Limits; claims without PA may be denied.
    • ED entries (excluded drugs) will not be covered.
    Denial Risk

    Prior authorization / quantity limit risk — claims may be denied without PA or if QL exceeded

    Presence of 'PA' or 'QL' on a drug entry indicates claims may be denied without prior authorization or if quantity limits are exceeded; follow the formulary entry and include documentation when submitting PA or billing.

    • If a PA is required, obtain approval before dispensing to prevent denial.
    • If QL applies, ensure dispensed amount does not exceed the listed QL or document medical necessity when requesting an override.
    Billing Rule

    PA/QL triggers — ensure authorization and correct B/D billing to avoid denials

    Coverage may be denied or subject to review when a drug is labeled with 'PA' or 'QL' without documented authorization or when Part B/Part D (B/D) billing indicators are not met; verify benefit channel and include setting-of‑use information for B/D items.

    • For B/D entries, submit clinical information describing the setting of use to determine correct billing channel.
    • Ensure PA approvals are in place for PA‑flagged drugs and that QL adherence is documented at claim submission.
    Denial Risk

    Excluded drugs — items marked ED will be denied if billed

    Some products are marked 'ED' (Excluded Drug) and will be denied if billed; check the formulary for ED entries (examples include benzonatate and certain sodium chloride inhalation solutions) before dispensing.

    • Benzonatate is listed as ED — not normally covered in this Medicare drug plan.
    • Excluded items will not count toward drug cost thresholds and are not covered.
    Prior Authorization

    Prior authorization required for listed specialty respiratory and related drugs (examples)

    Drugs with 'PA' in Requirements/Limits (examples: CAYSTON, KALYDECO, ORKAMBI, TRIKAFTA, ADEMPAS, ambrisentan, bosentan, OPSUMIT) require prior authorization — obtain PA prior to dispensing to avoid claim denials.

    • CAYSTON, KALYDECO, ORKAMBI, TRIKAFTA: PA and QL as shown per product line.
    • Pulmonary antihypertensives and CF agents frequently carry PA and LA flags.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Legend: tiers, abbreviations, and terms

    inv-113: Generic drugs definition
    Generic drugsFDA-approved products with the same active ingredient as the brand; generally substitutable and typically lower cost.
    SubstitutionGeneric drugs usually can be substituted for the brand name at the pharmacy without a new prescription, depending on state law.
    CoveragePriority Health Medicare covers both brand name and generic drugs; generics are listed on the formulary like brand products.
    inv-114: Biological products / Biosimilars definition
    Biological products / BiosimilarsBiological products are complex drugs; biosimilars are alternative versions that generally work similarly and may cost less.
    Interchangeable biosimilarsSome biosimilars are designated interchangeable and may be substituted for the original biological product at the pharmacy per state law without a new prescription.
    Formulary listingFormulary may list original biological products and biosimilars; substitution rules follow applicable state law and formulary policy.
    inv-115: Abbreviation list (B/D, PA, QL, HI, LA, NE, ED, ST)
    B/DPart B vs. Part D — may require documentation to determine coverage setting; provider may need to submit use/setting information.
    PAPrior Authorization — approval required from Priority Health Medicare before filling certain drugs.
    QLQuantity Limit — maximum quantity covered in the stated time frame (e.g., '30 EA per 30 days').
    Other abbreviationsHI = Home Infusion; LA = Limited Availability; NE = No Express Scripts; ED = Excluded Drug; ST = Step Therapy; ML = Milliliters; GM = Grams; EA = Each.
    inv-116: Tier codes (T1-T6 meaning)
    T1 - T6Formulary tiers where T1 = Preferred generic; T2 = Generic; T3 = Preferred brand; T4 = Non-preferred; T5 = Specialty; T6 = Infertility.
    Note on T5Tier 5 (Specialty) drugs are limited to a 30-day supply only.
    UsageTiers indicate coverage level and help determine possible requirements (PA, QL, ST, etc.).
    inv-117: Requirement abbreviations (PA, QL, HI, ST, LA, NE)
    PAPrior Authorization — approval required before coverage for drugs marked 'PA' on formulary listings.
    QLQuantity Limits — numeric maximums per period (EA, ML, GM) listed per product line.
    HIHome Infusion — indicates coverage under medical/home infusion benefit for specific IV formulations.
    STStep Therapy — trial of preferred drug(s) may be required prior to covering alternate drug when 'ST' indicated.
    inv-118: Tiers and abbreviations consolidated (T1-T6, PA, QL)
    T1 - Preferred genericPreferred generic tier designation used on formulary listing.
    T5 - SpecialtySpecialty tier — high-cost/specialty agents; supply limited to 30 days.
    AbbreviationsPA = Prior Authorization; QL = Quantity Limits; ST = Step Therapy; NE = No Express Scripts; B/D = Part B vs Part D; HI = Home Infusion; LA = Limited Availability; ED = Excluded Drug.
    inv-119: Abbreviations quick reference
    Quick referenceCommon shorthand used in the formulary: PA, QL, ED, HI, LA, B/D, ST, EA, ML, GM.
    EAEach — counting unit for tablets/capsules.
    ML / GMMilliliters and grams — used for liquids and topical formulations respectively.
    inv-120: Tier definitions and abbreviations (legend)
    PAPrior Authorization — authorization required prior to coverage for drugs marked 'PA'.
    QLQuantity Limits — maximum quantity allowed in the stated time frame as listed on each product line.
    B/DPart B vs. Part D — indicates billing/coverage channel and may require additional documentation.
    inv-127: PA definition (Prior Authorization required) & related
    PA — Prior AuthorizationAuthorization required from the plan before the drug will be covered.
    QL — Quantity LimitsMaximum quantity allowed in the stated time frame (e.g., '30 EA per 30 days').
    ED — Excluded DrugNot normally covered under the Medicare Prescription Drug Plan.
    inv-128: QL definition (Quantity Limits)
    QL definitionQuantity Limits — maximum quantity allowed in the stated time frame as listed on the formulary product line.
    EAEach — unit used for tablet/capsule counts.
    ML and GMMilliliters and grams — units for liquid and topical product quantity limits.

    Protections for members already receiving therapy

    Continuation of therapy protections

    Continuation of therapy protections — Covered when the member was taking the drug at the start of the coverage year and protections apply:

    Protections for continuing members: Drugs covered at the start of the coverage year generally will not be discontinued or have reduced coverage for that member during the coverage year except for immediate‑change scenarios (e.g., market withdrawal or immediate biosimilar substitution)

    Significant changes that do affect coverage will prompt mailed notice; members may request exceptions to continue therapy

    Step therapy flags and examples

    RequirementDescription
    Must try specified first-line drugs before coverage of alternative drugs
    Some drugs require trial of one or more preferred drugs (step therapy) before coverage of alternative drugs is allowed; consult the formulary for specific step therapy requirements.
    When ST AppearsAction
    When a drug entry includes the 'ST' flag in the Requirements/Limits column
    Follow Step Therapy: the member must try the preferred agent(s) indicated by the plan before the non-preferred alternative will be covered. If the preferred drug does not work, the plan will cover the alternative.
    ProductStep Therapy Note
    DIFICID oral suspension (reconstituted)
    Requires Step Therapy (ST) and has a quantity limit of 136 mL per 10 days; ST must be met prior to coverage.
    DIFICID oral tablet
    Requires Step Therapy (ST) and has a quantity limit of 20 EA per 10 days; ST must be met prior to coverage.
    Example Products Marked STFormulary Entry / Requirement
    FETZIMA
    Listed with Requirements/Limits = ST; QL (30 EA per 30 days) — Step Therapy required where ST is indicated.
    TRINTELLIX
    Listed with Requirements/Limits = ST; QL (30 EA per 30 days) — Step Therapy required where ST is indicated.
    vilazodone
    Listed with Requirements/Limits = ST where marked — Step Therapy required prior to coverage.
    eletriptan (and some triptans)
    Certain migraine agents are noted ST where marked; follow Step Therapy when ST appears on the drug line.
    ReferenceWhat the legend statesNotes
    Abbreviation legend (ST)
    ST = Step Therapy
    The formulary defines 'ST - Step Therapy' as a possible requirement in the legend, but specific step sequences or detailed rules are not provided in these chunks; consult the formulary entries for product-level ST details.
    Product Group / FormulationStep Therapy Indicator
    Paliperidone ER (extended-release) formulations
    Entries for paliperidone ER list 'ST' in Requirements/Limits (e.g., paliperidone ER 1.5/3/6/9 mg) — Step Therapy applies to these products.
    ContextImplication
    Formulary legend includes ST
    Step Therapy is referenced in the legend as 'ST', but no specific step edits or sequences are listed in these chunks — product lines must be checked for any ST requirement.
    ObservationInterpretation
    ST flag appears in formulary segments
    The ST flag is used as an indicator in the formulary legend; however, some segments show the flag without detailed step rules in these excerpts.
    SectionDetail
    Formulary marking of ST
    ST marks where applicable per the legend; detailed step therapy rules are not present in the provided chunks — check specific drug lines for ST requirements.
    Product ExampleRequirement
    calcitriol external
    Flagged with ST in the formulary excerpt — indicates Step Therapy applies for the external calcitriol entry where shown.
    Product ExampleRequirement
    clotrimazole-betamethasone (example topical entries)
    At least one clotrimazole-betamethasone external entry is noted with ST; follow Step Therapy when ST is listed on the product line.
    ReferenceFinding
    Abbreviations and legend referencing ST
    ST is referenced but the provided chunks do not show the step sequences or trials required — product-level entries may contain details.
    Formulary LegendMeaning
    ST - Step Therapy
    Formulary references 'ST - Step Therapy' as a possible requirement in the legend; specific step therapy rules are not included in these excerpted chunks.
    Ophthalmic AgentsStep Therapy Notes
    difluprednate (ophthalmic)
    Designated 'ST' in the ophthalmic section; step therapy must be met prior to coverage where ST is indicated.
    loteprednol products (ophthalmic gel/suspension)
    Some loteprednol formulations are designated 'ST' — follow Step Therapy when ST appears on these lines.
    Legend ReferenceContent
    ST in the formulary legend
    Step Therapy is listed as 'ST' in the abbreviation legend; the provided chunks do not include full step therapy sequences for products.

    Numerical dispensing limits by product

    inv-151: XARELTO 10MG (example) and related QL examples
    XARELTO 10 mg (example)30 tablets per prescription (QL 30 EA per 30 days as illustrated in document examples)
    TRADJENTAQL examples include 30 EA per 30 days and alternate listing of 60 EA per 30 days depending on entry
    TRULICITY auto-injectorQL (2 ML per 28 days) shown for auto-injector presentations

    Home infusion and billing channel notes

    Note
    Note
    Note

    Biologic and biosimilar handling

    Note